Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Recursion, founded in 2013 and headquartered in Salt Lake City, Utah, is a clinical-stage biotechnology company at the forefront of integrating technological innovations across various scientific disciplines. We specialize in industrializing drug discovery by leveraging cutting-edge technology to create virtuous cycles of learning around datasets, primarily serving the biopharmaceutical industry.
Since its inception, Recursion has raised an impressive total of $509.79 million in funding, demonstrating significant investor interest in its innovative approach to drug discovery. The company's unique blend of biology, chemistry, automation, data science, and engineering positions it as a potential disruptor in the biotechnology sector.
While there is currently no concrete information available regarding Recursion's IPO prospects, the company's substantial funding and innovative approach in the biotechnology industry may attract attention from potential investors interested in Recursion stock. However, it's important to note that any discussions about a possible Recursion IPO or the ability to buy Recursion shares remain speculative at this time.
As with any potential investment opportunity, those interested in investing in Recursion stock or looking for a Recursion ticker symbol should continue to monitor official company announcements and verified financial news sources for the most up-to-date and accurate information.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Recursion's IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotechnology sector. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry pioneers like Recursion before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
